Recent studies have revealed that inhibitors targeting BChE, or dual inhibitors of both cholinesterases (AChE and BChE), offer a more effective treatment for AD with fewer side effects compared to AChE-specific inhibitors. Here, BCHE is linked to Alzheimer disease.